DE69434137T2 - Chaperonin 10 - Google Patents

Chaperonin 10 Download PDF

Info

Publication number
DE69434137T2
DE69434137T2 DE69434137T DE69434137T DE69434137T2 DE 69434137 T2 DE69434137 T2 DE 69434137T2 DE 69434137 T DE69434137 T DE 69434137T DE 69434137 T DE69434137 T DE 69434137T DE 69434137 T2 DE69434137 T2 DE 69434137T2
Authority
DE
Germany
Prior art keywords
cpn10
epf
protein
peptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434137T
Other languages
German (de)
English (en)
Other versions
DE69434137D1 (en
Inventor
Halle Morton
Alice Christina Cavanagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland
Original Assignee
University of Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by University of Queensland filed Critical University of Queensland
Application granted granted Critical
Publication of DE69434137D1 publication Critical patent/DE69434137D1/de
Publication of DE69434137T2 publication Critical patent/DE69434137T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
DE69434137T 1993-11-30 1994-11-30 Chaperonin 10 Expired - Lifetime DE69434137T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPM270593 1993-11-30
AUPM270593 1993-11-30
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10
AUPM823494 1994-09-16
PCT/AU1994/000740 WO1995015338A1 (en) 1993-11-30 1994-11-30 Chaperonin 10

Publications (2)

Publication Number Publication Date
DE69434137D1 DE69434137D1 (en) 2004-12-23
DE69434137T2 true DE69434137T2 (de) 2005-12-01

Family

ID=25644587

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434137T Expired - Lifetime DE69434137T2 (de) 1993-11-30 1994-11-30 Chaperonin 10

Country Status (11)

Country Link
US (3) US6113899A (enExample)
EP (2) EP0731811B1 (enExample)
JP (3) JP3987104B2 (enExample)
AT (1) ATE282634T1 (enExample)
AU (2) AU684578B2 (enExample)
CA (1) CA2177179C (enExample)
DE (1) DE69434137T2 (enExample)
ES (1) ES2233938T3 (enExample)
NZ (2) NZ276670A (enExample)
PT (1) PT731811E (enExample)
WO (2) WO1995015338A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015338A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10
JP2001509396A (ja) * 1997-07-10 2001-07-24 メディカル リサーチ カウンシル シャペロン断片
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
AU2002317013B2 (en) * 2001-06-27 2007-11-01 Janssen Pharmaceutica N.V. EPF receptor assays, compounds and therapeutic compositions
AU2002952492A0 (en) * 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
JP2007517808A (ja) 2004-01-16 2007-07-05 キュビオ リミテッド Ｔｏｌｌ様受容体誘導性のサイトカインおよびケモカイン分泌のシャペロニン１０調節
EP2463307A1 (en) 2005-08-31 2012-06-13 CBIO Limited Modified chaperonin 10
CA2626692A1 (en) * 2005-10-20 2007-04-26 Cbio Limited Treatment of hypersensitivity
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
MX2008011167A (es) 2006-03-02 2008-11-12 Cbio Ltd Regulaciòn de respuestas inmunes mediante la modulaciòn de la funciòn de cèlulas presentadoras de antìgenos.
CA2720617A1 (en) 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
NZ599666A (en) * 2009-10-09 2014-11-28 Cbio Ltd Chaperonin 10 variants
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
KR101776013B1 (ko) * 2017-05-26 2017-09-07 (주)넥스젠바이오텍 항산화 활성 및 피부 세포 증식 효과가 증가한 열 충격 단백질 10과 브라제인 단백질의 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선용 화장료 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU599021B2 (en) * 1985-03-12 1990-07-12 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
EP0262119A1 (en) * 1985-03-12 1988-04-06 University Of Queensland Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody
EP0345260A4 (en) * 1986-12-22 1990-05-14 Univ Queensland METHOD FOR TREATING MAMMALS USING EARLY PREGNANCY FACTOR (EPF) ANTIBODIES.
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
WO1995015338A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Chaperonin 10

Also Published As

Publication number Publication date
WO1995015339A1 (en) 1995-06-08
AU684577B2 (en) 1997-12-18
EP0731811A1 (en) 1996-09-18
AU1103495A (en) 1995-06-19
NZ276672A (en) 1998-01-26
EP0733071A4 (en) 1997-02-26
JPH09506431A (ja) 1997-06-24
EP0733071A1 (en) 1996-09-25
US7358329B2 (en) 2008-04-15
JP3986481B2 (ja) 2007-10-03
CA2177179C (en) 2006-10-17
JP3987104B2 (ja) 2007-10-03
US6113899A (en) 2000-09-05
AU1103695A (en) 1995-06-19
ATE282634T1 (de) 2004-12-15
JPH09505811A (ja) 1997-06-10
US6417334B1 (en) 2002-07-09
EP0731811B1 (en) 2004-11-17
PT731811E (pt) 2005-04-29
DE69434137D1 (en) 2004-12-23
NZ276670A (en) 1998-01-26
US20030175280A1 (en) 2003-09-18
EP0731811A4 (en) 2003-05-28
WO1995015338A1 (en) 1995-06-08
JP2004067698A (ja) 2004-03-04
JP3545408B2 (ja) 2004-07-21
AU684578B2 (en) 1997-12-18
ES2233938T3 (es) 2005-06-16
CA2177179A1 (en) 1995-06-08

Similar Documents

Publication Publication Date Title
DE3688333T2 (de) Antikörper gegen Polypeptide, die gegen Peptide oder Proteine mit mindestens teilweise bekannter Aminosäure oder kodierender Nukleotidsequenz komplementär sind und diesbezügliches Aufbauverfahren.
DE69017753T2 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper.
Mannick et al. Prolongation of allograft survival by an alpha globulin isolated from normal blood
DE69032922T2 (de) Menschliches intra-akrosomales spermaantigen zur verwendung in einem empfängnisverhütungsimpfstoff
DE69837678T2 (de) Compositions zur inhibierung der proliferation glatter muskulatur und verfahren zur diagnose von arteriosklerose
Spitzauer et al. Molecular characterization of dog albumin as a cross-reactive allergen
DE69636733T2 (de) Antikörperreinigung durch hydrophobe wechselwirkungchromatografie bei niedrigem ph
EP0731811B1 (en) Chaperonin 10
DE69231062T3 (de) Morphogen-induzierte Modulation von entzündlichen Antworten
DE68923675T2 (de) Interzellulare Adhäsions-Moleküle und deren Bindungsliganden.
DE69911401T2 (de) Immunoregulator
DE69132653T2 (de) Birkenpollenallergen p14 zur diagnose und therapie von allergischen krankheiten
CA2176948C (en) Chaperonin 10
Bacha et al. Anti‐arthritic effects demonstrated by an interleukin‐2 receptor‐targeted cytotoxin (DAB486IL‐2) in rat adjuvant arthritis
EP0876610B1 (en) A method and use of polypeptide in sperm-egg binding to enhance or decrease fertility
Wood et al. Apical and basal-lateral Na/K-ATPase in rat lacrimal gland acinar cells.
EP1277837A2 (de) Epididymis-spezifische DNA-Sequenzen und deren Verwendung
DE3881698T2 (de) Lectine, die beta-d-galactosid binden.
EP0950065B1 (de) Peptide als diagnostikum und therapeutikum für autoimmunerkrankungen
DE3854740T2 (de) Menschlicher monoklonaler antikörper gegen candida.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition